BOSI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.124
EU - Europa 15.181
AS - Asia 2.792
AF - Africa 95
SA - Sud America 12
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 5
Totale 44.219
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.052
RU - Federazione Russa 4.311
PL - Polonia 4.094
IT - Italia 1.575
IE - Irlanda 1.484
SE - Svezia 1.464
SG - Singapore 901
UA - Ucraina 624
HK - Hong Kong 613
CN - Cina 594
DE - Germania 503
FI - Finlandia 426
GB - Regno Unito 287
IN - India 275
CH - Svizzera 202
TR - Turchia 137
JO - Giordania 107
FR - Francia 88
VN - Vietnam 86
CA - Canada 71
CI - Costa d'Avorio 57
ES - Italia 35
KR - Corea 32
BE - Belgio 26
JP - Giappone 20
SC - Seychelles 20
NL - Olanda 18
AT - Austria 17
MU - Mauritius 8
AE - Emirati Arabi Uniti 6
TW - Taiwan 6
AR - Argentina 5
AU - Australia 5
EU - Europa 5
NZ - Nuova Zelanda 5
TH - Thailandia 5
ZA - Sudafrica 5
CO - Colombia 4
ID - Indonesia 4
DK - Danimarca 3
IR - Iran 3
LT - Lituania 3
RO - Romania 3
BG - Bulgaria 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
EE - Estonia 2
KE - Kenya 2
NO - Norvegia 2
PE - Perù 2
SM - San Marino 2
TN - Tunisia 2
AZ - Azerbaigian 1
BD - Bangladesh 1
EC - Ecuador 1
EG - Egitto 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
IM - Isola di Man 1
LU - Lussemburgo 1
MX - Messico 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 44.219
Salva come PNG Salva come JPEG
Città #
Santa Clara 5.015
Warsaw 4.086
Fairfield 3.508
Chandler 1.842
Ashburn 1.604
Woodbridge 1.599
Dublin 1.481
Seattle 1.431
Cambridge 1.338
Houston 1.177
Wilmington 1.161
Jacksonville 1.020
Singapore 696
Ann Arbor 556
Princeton 548
Altamura 489
Lawrence 484
Boardman 285
Boston 280
Hong Kong 251
Mumbai 249
Medford 237
Beijing 226
Bern 192
Buffalo 179
San Diego 176
Florence 153
Moscow 113
Izmir 112
Shanghai 103
Falls Church 84
New York 79
Norwalk 75
Salerno 65
Dong Ket 64
Kent 62
Milan 62
Abidjan 57
Bremen 57
Toronto 54
Rome 53
Los Angeles 48
Hillsboro 46
Yubileyny 35
Andover 33
Verona 33
Helsinki 32
Barcelona 31
London 30
Seoul 26
Brussels 25
Phoenix 25
West Jordan 24
Frankfurt Am Main 22
Turin 21
Redwood City 19
Munich 18
Pune 18
Auburn Hills 17
Guangzhou 17
Vienna 15
Old Bridge 13
Laurel 11
Napoli 11
Padova 11
Shenzhen 11
Dearborn 10
Falkenstein 10
Redmond 10
Bologna 9
Nanjing 9
Palermo 8
Naples 7
Tappahannock 7
Wuhan 7
Abu Dhabi 6
Acton 6
Amman 6
Brescia 6
Detroit 6
Fuzhou 6
Hangzhou 6
Philadelphia 6
Hounslow 5
Jinhua 5
Latina 5
Parma 5
Saint Petersburg 5
San Mateo 5
Trumbull 5
Zhengzhou 5
Aprilia 4
Catania 4
Cecina 4
Cedar Knolls 4
Chicago 4
Chiswick 4
Dallas 4
Farra di Soligo 4
Gesualdo 4
Totale 32.096
Salva come PNG Salva come JPEG
Nome #
Lesioni cutanee «specifiche» in corso di leucemia linfatica cronica. 478
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 339
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 291
Patients with ≥ 20 × 10(9)/L Platelets at Baseline May Have a Prompt Response to Romiplostim During the Early Phase of Treatment: an Italian Single-Institution Experience. 288
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. 286
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 284
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 279
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 273
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 267
Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model 266
Dendritic cells with lymphocyte stimulating activity differentiate from human CD133 positive precursors. 266
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. 264
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. 263
Hepcidin levels and their determinants in different types of myelodysplastic syndromes 261
EZH2 mutational status predicts poor survival in myelofibrosis. 257
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. 257
CD20 expression has no prognostic role in Philadelphia-negativeB-precursor acute lymphoblastic leukemia: new insights from the molecularstudy of minimal residual disease. 256
Primary cutaneous follicular centre- cell lymphoma- a lymphoproliferative disease with favourable prognosis. 255
[The treatment of diffuse cutaneous systemic sclerosis with autologous hemopoietic stem cells transplantation (HSCT): our experience on 2 cases]. 251
Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN 250
No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients. 244
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 238
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. 237
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. 229
CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. 223
Dendritic cells in the skin after allogeneic bone marrow transplantation: immunohistochemical and electron microscopic monitoring 221
Increase in FOXP3(+) Regulatory T Cells in GVHD Skin Biopsies Is Associated with Lower Disease Severity and Treatment Response 218
Familial Hemophagocytic Lymphohistiocytosis May Present during Adulthood: Clinical and Genetic Features of a Small Series 213
The use of Deauville 5-point score could reduce the risk of false-positive fluorodeoxyglucose-positron emission tomography in the posttherapy evaluation of patients with primary bone lymphomas 212
Localized scleroderma-like lesions in autologous bone marrow transplantation. 197
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 191
Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. Experience. 183
Overexpression of microRNA-16-2 contributes to the abnormalerythropoiesis in polycythemia vera. 163
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial 154
Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. 152
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 151
18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. 150
Inorganic nanoparticles as potential regulators of immune response in dendritic cells 150
Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. 147
Time related variations in stem cell harvesting of umbilical cord blood 145
The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study 142
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 141
Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. 140
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 140
Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia 140
Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation 137
Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. 136
Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. 135
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 135
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. 134
Insights into JAK2-V617F mutation in CML. 133
Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance. 133
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. 131
Treatment options for essential thrombocythemia and polycythemia vera 131
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR 131
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 131
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 131
New patterns of relapse in multiple myeloma: A case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation 131
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease 130
A case of disseminated Blastic Plasmocytoid Dendritic Cell Neoplasm 130
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. 129
Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. 129
Neutral maltase of human granulocytes: localization on the extracytoplasmic side of the plasma membrane and some properties 129
Acquired severe aplastic anemia after H1N1 influenza virus vaccination successfully treated with allogeneic bone marrow transplantation 129
Chemotherapy-related nail toxicity 129
Molecular characterization of Acinetobacter isolates collected in intensive care units of six hospitals in Florence, Italy, during a 3-year surveillance program: a population structure analysis 128
The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo 127
Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells. 127
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. 127
Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment 127
Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42] 127
Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases 126
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 126
ATP modulates cell proliferation and elicits two different electrophysiological responses in human mesenchymal stem cells. 126
Aztreonam versus colistin-neomycin for selective decontamination of the digestive tract in patients undergoing bone marrow transplantation: a randomized study. 125
Romiplostim before splenectomy in a patient with aggressive non-Hodgkin lymphoma and poor response to platelet transfusions 125
Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. 125
Neutral Maltase Activity in Leucocytic PopulationNew Trends in Experimental Hematology, Serono Simposia 124
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience 124
Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. 124
Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide 124
A life-threatening ruxolitinib discontinuation syndrome 124
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. 123
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey 122
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. 122
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 122
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. 121
Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. 121
CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. 121
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 121
The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL) 121
Attività della maltasi neutra sulla membrana dei granulociti.31° Congresso Nazionale S.I.B. Rimini, 15-18 Settembre 1985. Abs. B21 120
Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment 120
A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach 120
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 120
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. 120
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients 120
Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML 120
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. 120
Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis. 119
Totale 17.095
Salva come PNG Salva come JPEG
Categoria #
all - tutte 116.727
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 116.727
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.847 0 0 0 0 0 964 834 1.011 796 472 625 145
2020/20214.799 422 376 412 448 166 642 197 416 435 589 303 393
2021/20222.986 75 308 223 129 133 143 130 214 169 116 485 861
2022/20237.545 836 1.314 308 610 666 1.362 794 430 692 48 221 264
2023/20242.302 144 304 465 101 143 293 94 386 27 105 127 113
2024/202511.774 620 1.848 1.057 2.353 4.400 1.496 0 0 0 0 0 0
Totale 44.640